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licenses/by/4.0/).Abstract Background: The coronavirus disease 2019 (COVID-19) pandemic, caused by se-
vere acute respiratory syndrome coronavirus 2, has inevitable consequences for medical care
of patients without COVID-19. To assess the impact of this pandemic on oncological care, a
nationwide survey was conducted among patients with cancer in the Netherlands.
Methods: The patients’ perspective on oncological care was investigated using an online sur-
vey between March 29th 2020 and April 18th 2020. The survey consisted of 20 questions on
four topics: patients’ characteristics, contact with the hospital, consequences of the COVID-
19 pandemic and concerns about COVID-19.
Results: Five thousand three hundred two patients with cancer completed this nationwide sur-
vey. Overall, 30% of patients reported consequences for their oncological treatment or follow-
up. In the majority of cases, this resulted in conversion from hospital visit to consultation byof Medical Oncology and Radiology & Nuclear Medicine, Erasmus MC Cancer Institute, Dr. Molewa-
etherlands.
usmc.nl (A.A.M. van der Veldt).
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K. de Joode et al. / European Journal of Cancer 136 (2020) 132e139 133phone or video. The most frequently adjusted treatments were chemotherapy (30%) and
immunotherapy (32%). Among patients with delay and discontinuation of treatment, 55%
and 63% of patients, respectively, were (very) concerned about these consequences of the
COVID-19 pandemic. Consequences were independent of regional differences in COVID-19
incidence. However, patients in regions with high COVID-19 incidence were significantly more
concerned.
Conclusion: This is the first study investigating perspectives of patients with cancer during the
COVID-19 pandemic. The study demonstrates the significant impact of the COVID-19 crisis
on oncological care, indicating the need for psycho-oncological support during this pandemic.
ª 2020 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC
BY license (http://creativecommons.org/licenses/by/4.0/).1
1. Introduction
The COVID-19 pandemic, caused by severe acute res-
piratory syndrome coronavirus 2 (SARS-CoV-2) [1,2], is
exhausting healthcare system capacities and has major
consequences on noneCOVID-19 medical care [3]. Be-
sides limiting capacity of medical care, in general, the
COVID-19 pandemic has specific impact on oncological
care [4].
First, it has been reported that patients with an
(active) malignancy may have an increased risk of
COVID-19 [5e7]. Second, malignancy may be an inde-
pendent risk factor of a more severe course of COVID-
19 [5,7e9]. Third, systemic anti-cancer treatment, such
as chemotherapy, may increase the risk of a severe
infection [10]. Fourth, hospital visits that are required
for many cancer treatments may put patients with can-
cer at risk to be infected with SARS-CoV-2 [5,8].
Considering these factors, physicians and patients are
confronted with unprecedented uncertainties about the
safety of cancer treatment during this pandemic,
balancing between the risk of exposure to SARS-CoV-2
and the risks of postponing life-saving or life-prolonging
cancer treatments. Therefore, several (inter)national
societies and committees have developed guidelines for
oncology physicians [11e14]. Until now, these guide-
lines are only based on expert opinions. Similarly, sci-
entific evidence has not yet been generated on the impact
of COVID-19 on oncological care and patients’
perspectives.
In this study, the impact of the COVID-19 pandemic
on patients with cancer and the consequences for their
treatment was investigated in the Netherlands. To assess
patients’ perspectives on the consequences of the
COVID-19 pandemic on cancer treatment and follow-
up, a nationwide survey was conducted among patients
with cancer during the national lockdown [15,16].2. Methods
2.1. Survey
A survey for patients with cancer was developed to
evaluate the impact of the COVID-19 pandemic on
hospital appointments and cancer treatment. The survey
contained 20 questions on four topics: patients’ char-
acteristics, contact with the hospital, consequences of
the COVID-19 pandemic (consultations, treatment and
follow-up) and concerns about COVID-19 (appendix 1).
This online survey was developed by the Dutch
Federation of Cancer Patients Organisations (Neder-
landse Federatie van Kankerpatiëntenorganisaties
[NFK]1 [17]) in close collaboration with oncology phy-
sicians and representatives of patient advocacy groups
and the Dutch Multidisciplinary Oncology Foundation
(Stichting Oncologische Samenwerking (SONCOS)2
[18]). NFK, Dutch hospitals, Dutch Cancer
Society and cancer-specific patient advocacy groups
distributed the survey to patients by direct mailing, an-
nouncements on websites and social media. The survey
was open between March 29th 2020 and April 18th
2020.
2.2. Privacy
No personal data were collected, and questionnaires
could not be traced back to the patients.
2.3. Regional classification of COVID-19 in the
Netherlands
To evaluate the impact of COVID-19 incidence on
hospital visits and treatment, regions in the NetherlandsNFK federates 19 national patient advocacy groups for cancer and
advises the government, health authorities and health care pro-
fessionals in the Netherlands.
2 SONCOS, an initiative by the Dutch societies of medical oncology,
radiation oncology and surgical oncology, represents 29 scientific so-
cieties/organisations involved in cancer care and acts as a national
platform to improve the quality of cancer care.
Fig. 1. Number of patients with a positive test for SARS-CoV-2 in the Netherlands during the three-week period of the survey on (a)








<65 years 3422 65
65 years 1880 35
Region in the Netherlands




Curable disease 793 15
Incurable disease 1907 36
Unknown 598 11
Treatment setting
Awaiting treatment 250 5
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with COVID-19. In the Netherlands, the COVID-19
pandemic is monitored by the National Institute for
Public Health and the Environment [19]. Patients are
registered COVID-19 positive when they have a positive
test for SARS-CoV-2 using reverse transcription poly-
merase chain reaction.
The country of the Netherlands has 17.4 million in-
habitants [20] and is divided into twelve regions, called
provinces, according to geographic location. For the
analyses in the present study, provinces were classified
according to the number of COVID-19epositive pa-
tients. A province was defined as code red when there
were 100 COVID-19epositive patients per 100,000
inhabitants in that particular province on March 29th
2020 [19]. To determine the regional development of
COVID-19 in the three-week period of the survey, the
number of COVID-19epositive patients per 100,000
inhabitants per province on April 18th 2020 was
calculated.
Under treatment 2391 45
Follow-up 2661 50
Cancer diagnosis
Bladder and renal cell cancer 214 4
Brain tumor 45 1
Breast cancer 1187 22
Colorectal cancer 296 6
Gastric and oesophageal cancer 92 2
Gynaecological cancer 177 3
Head and neck cancer 77 1
Haematological malignancy 1660 31
Lung cancer 622 12
Melanoma and skin cancer 209 4
Mesothelioma 34 1
Pancreatic cancer 55 1
Prostate cancer 160 3
Sarcoma 56 1
Testicular cancer 37 1
Other 381 7
COVID-19 Z coronavirus disease 2019.2.4. Data analysis
Baseline characteristics and survey responses were ana-
lysed using descriptive statistics. Cancer diagnosis not
represented by a patient advocacy group (mainly rare
cancers) or reported as unknown was grouped as ‘other’.
The following subgroups were analysed: age (age <65
vs. age 65 years), treatment setting (awaiting treat-
ment, under treatment, follow-up), disease setting
(cured, curable, incurable) and region of the patients’
hospital (code red vs. other). Regarding questions on
concerns, the four selectable answers were categorised
into ‘not/slightly concerned’ (i.e. not or slightly con-
cerned) and ‘(very) concerned’ (i.e. concerned and very
concerned). The Pearson’s chi-square test was used totest for differences between specific groups. All statisti-
cal tests were performed two sided. P-values of <0.05
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analysed using IBM SPSS statistics, version 25.
3. Results
3.1. COVID-19 in the Netherlands
At the time the survey was launched on March 29th
2020, the southern part of the Netherlands suffered
severely from the COVID-19 pandemic. On March 29th
2020, code red was applicable to two provinces (i.e.
Noord-Brabant and Limburg) (118 and 107 patients
with COVID-19 per 100,000 inhabitants, respectively;
Fig. 1a). At the time the survey was closed on April 18th
2020, Noord-Brabant and Limburg still had the highest
number of patients with COVID-19 per 100,000 in-
habitants (262 and 293 patients with COVID-19,
respectively; Fig. 1b). In the three-week period of the
survey, the incidence of patients with COVID-19 also
increased in other regions. For example, in Friesland, a
northern province with the lowest incidence, the number
of patients with COVID-19 increased from 18 to 70 per
100,000 inhabitants.
3.2. Patients’ characteristics
The survey was completed by 5302 patients with cancer
(Table 1). Most (62%) respondents completed the survey
in the first week, that is, March 29th to April 3rd. In
total, 3413 (64%) patients were women, and most pa-
tients (65%) were <65 years. Haematological malig-
nancies (31%), breast cancer (22%) and lung cancer
(12%) were the most frequent cancer diagnoses. Only 21
(0.4%) patients reported to have been tested positive for
SARS-CoV-2.
According to disease setting, 36% of patients had
incurable disease, whereas 15% and 38% of patients had
curable or cured disease, respectively. For 11% of pa-
tients, the (expected) outcome of their disease was ‘un-
known’. As the intention of treatment (curative vs.
palliative) could affect the nature of adjustments in
treatment, the ‘unknown’ group was excluded from
further analyses. Elderly patients more frequently re-
ported to have incurable disease than younger patients
(51% vs. 35%, p < 0.05). According to treatment setting,
2661 (50%) patients had completed oncological treat-
ment and were in follow-up, whereas 250 (5%) and 2391
(45%) patients were awaiting or currently under treat-
ment, respectively.
3.3. Contact with the hospital
Half of the patients (nZ 2664, 50%) had been in contact
with their hospital about the consequences of the
COVID-19 pandemic for their individual situation in
relation to their cancer treatment or follow-up. Among
patients who were in follow-up, 36% of patients hadcontact with the hospital, whereas 52% and 69% of
patients who were awaiting and under treatment had
contact with the hospital, respectively (p < 0.05). Pa-
tients who completed the survey between April 4th and
April 17th had more frequently contact with the hospital
than patients who completed the survey in the first week
(57% vs. 48%, p < 0.05). Overall, 75% of all patients
reported that the COVID-19 pandemic did not influence
their behaviour to contact the hospital; however, 19% of
patients reported that they were less inclined to contact
the hospital.3.4. Consequences for treatment and hospital visits
The COVID-19 pandemic led to consequences for
treatments and hospital visits, mostly initiated by the
hospital (79%). The majority of patients (72%) re-
ported that they had been informed adequately by the
hospital about the reason for the consequences for
treatment and hospital visits. Among the 2664 patients
who had had contact with the hospital, 1583 patients
(i.e. 30% of all respondents) experienced consequences
for their treatment or follow-up. Patients with incurable
disease or under treatment most frequently experienced
consequences (Figs. 2 and 3). Overall, the most
frequently reported consequence was the conversion
from hospital visit to consultation by phone or video,
which was reported in 817 of 1583 (52%) patients who
experienced consequences. Treatment was adjusted in 7
of 250 patients (3%) and in 162 of 2391 patients (7%)
who were awaiting and under treatment, respectively.
Treatment was postponed in 39 of 250 patients (16%)
and in 279 of 2391 patients (12%) who were awaiting
and under treatment, respectively. Treatment changes
included adjustment, delay and discontinuation of
treatment. Overall, treatment was changed in 49 of 250
patients (20%) and in 480 of 2391 patients (20%) who
were awaiting and under treatment, respectively. In
patients with adjusted treatment, chemotherapy (30%)
and immunotherapy (32%) were most frequently
adjusted (Fig. 4a). Delay and discontinuation of treat-
ment also mainly included chemotherapy and immu-
notherapy (Fig. 4b and c).3.5. Concerns
Many patients were concerned about the consequences
of the COVID-19 pandemic for their cancer treatment
or follow-up. Among patients with delay and discon-
tinuation of treatment, 55% and 62% of patients were
concerned, respectively. Among patients who did not
experience consequences yet, 24% of patients were (very)
concerned about potential consequences for their treat-
ment or follow-up. In the setting of cured disease or
follow-up, 87% and 83% of patients were not/slightly
concerned, respectively.
Fig. 2. Experienced consequences for treatment and follow-up visits of 4704 patients according to disease setting. Patients with ‘unknown’
disease setting were excluded. Patients answered whether they experienced consequences as ‘yes’, ‘not yet’ or ‘no’.
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be infected with SARS-CoV-2. Patients who were under
treatment were more often (very) concerned to be
infected than patients in follow-up (54% vs. 40%,
p < 0.05). Patients with incurable disease were also more
often (very) concerned than patients with curable or
cured disease (55% vs. 50% and 37%, respectively,
p < 0.05).3.6. Patients’ perspectives in most affected COVID-19
regions
According to regional classification, surveys were
completed by 834 (16%) patients in code red regions (23
completed surveys per 100,000 inhabitants) and 4468
(84%) patients in other regions (33 completed surveys
per 100,000 inhabitants). In regions with code red, ap-
pointments were more frequently cancelled and treat-
ments were more frequently adjusted, but these
differences were not statistically significant as compared
with other regions. In three specific situations, however,
differences were found between code red and otherregions. First, cancellation of appointments was more
frequently initiated by hospitals in code red regions
(99% vs. 92%, p < 0.05). In code red regions, patients
more frequently reported symptoms probably related to
COVID-19 (13.3% vs. 10%, p < 0.05). Finally, patients
in code red regions were more concerned to be infected
with SARS-CoV-2 than patients in the other regions
(51% vs. 46%, p < 0.05).4. Discussion
According to many expert opinions, oncology physi-
cians are very concerned about the impact of the
COVID-19 pandemic on oncological care, in particular,
because more COVID-19 outbreaks are expected.
Nevertheless, a comprehensive study on patients’ per-
spectives has been lacking. To the best of our knowl-
edge, this is the first study investigating perspectives of
patients with cancer during the COVID-19 pandemic.
The survey was conducted among 5302 patients with
cancer in the Netherlands. As reported by these patients,
the COVID-19 pandemic has significant impact on their
Fig. 3. Experienced consequences for treatment and follow-up visits of 5302 patients according to treatment setting. Patients answered
whether they experienced consequences as ‘yes’, ‘not yet’, or ‘no’.
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consequences regarding their oncological treatment or
follow-up, mostly initiated by the hospital. The most
frequently adjusted therapies were chemotherapy and
immunotherapy.
Although 50% of patients had had contact with their
hospital about their individual situation, 19% of patientsFig. 4. Adjusted treatment (a; n Z 213), postponed treatment (b; n Z
modality.was more reluctant to contact the hospital during the
COVID-19 pandemic. This hesitancy to consult the
hospital for noneCOVID-19 diseases is an issue of in-
ternational concern. For example, a large reduction in
hospital admissions for acute coronary syndrome was
noticed since the COVID-19 outbreak in Italy [21]. In
addition, the incidence of new cancer diagnoses has406) and cancelled treatment (c; n Z 58) according to treatment
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temporarily discontinuation of screening programmes
for cancer [23]. In the Netherlands, a 30% decrease in
the incidence of new cancer diagnosis was observed in
March and April 2020 [24].
Most patients with curable disease continued their
treatment unchanged, whereas treatment was more
frequently postponed in patients with incurable disease.
As compared with patients with curable or cured dis-
ease, patients with incurable disease were more con-
cerned about the COVID-19 pandemic and the risk of
infection with SARS-CoV-2. These concerns may be
explained by fear not to be admitted to the intensive care
unit in case of severe COVID-19. This fear is conceiv-
able, as strict triage criteria were expected due to ca-
pacity issues and restrictive national guidelines for the
treatment of patients with incurable malignancies.
Although patients treated in code red regions were
more concerned about the consequences of their onco-
logical treatment or follow-up, the absolute differences
in regional adjustments were negligible. It is conceivable
that these nationwide adjustments are the result of na-
tional advices on oncological treatment during the
COVID-19 pandemic. On March 22nd, the Dutch
Multidisciplinary Oncology Foundation (SONCOS)
and other organisations have issued guidelines with
practical adjustments to preserve the continuity of can-
cer care as much as possible. To reduce the risk for in-
hospital transmissions, treatment-related hospital-
isations were limited, thereby anticipating on the ex-
pected capacity issues. In addition, the lack of scientific
evidence and concerns about safety of cancer treatments
may have contributed to nationwide adjustments of
treatment.
Although the Netherlands is a relatively small Eu-
ropean country, the present study serves as a represen-
tative model to evaluate the impact of the COVID-19
pandemic on oncological care. As all patients have equal
access to medical care in the Netherlands, reimburse-
ment issues have most likely not contributed to the re-
sults of the present study. Therefore, the impact of the
COVID-19 pandemic on oncological care is expected to
be even higher in countries with unequal access to
oncological care [25]. As comparable with other coun-
tries, there were significant differences in COVID-19
incidence between regions in the Netherlands (Fig. 1a
and b). Therefore, the present study, which has nation-
wide coverage, serves as a representative model for pa-
tients’ perspectives in a country during the COVID-19
pandemic. Nevertheless, cultural differences and
different national recommendations on cancer treatment
may significantly influence the behaviour of patients
with cancer and oncology physicians during the
COVID-19 pandemic.
As no personal data were collected and question-
naires could not be traced back to patients, clinical data
could not be monitored. In particular, it can be difficultfor patients to distinguish incurable (i.e. palliative) from
curable disease setting. Besides disease setting, treatment
restrictions, such as restrictions on resuscitation and
mechanical ventilation, could have influenced treatment
adjustments and patients’ perspectives. As the survey
did not contain questions about such treatment re-
strictions, this is a potential limitation of the survey.
Another limitation is a potential selection bias, which
may be induced by the design of this study. In the
Netherlands, 347,121 people are suffering from cancer
[26], whereas only a fraction, 5302 (0.9%) has partici-
pated in the current survey. Nevertheless, the survey had
nationwide coverage, and patients from all regions in
the Netherlands participated in the survey.
In general, most patients were (very) concerned about
the impact of the COVID-19 pandemic on their onco-
logical treatment or follow-up. In particular, patients
treated in code red regions were more concerned than
patients in other regions, independent of the treatment
adjustments. These findings indicate that all patients
could benefit from more psycho-oncological support
and information, for example, by use of webinars.
Additional support for patients facing the daily conse-
quences of the COVID-19 pandemic would be
beneficial.
This COVID-19 pandemic has inevitable conse-
quences for healthcare systems and, as underscored by
the present study, adjustments in noneCOVID-19
medical care cannot be avoided. In the near future, it
will be a challenge to reorganise oncological care while
still facing the COVID-19 pandemic. In the meantime,
we will be awaiting the impact of all adjustments of
oncological care on survival and quality of life of pa-
tients with cancer.Funding
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